Antitumor dinuclear platinum(II) complexes derived from a novel chiral ligand

Syntheses, crystal structures, and biological evaluations of new dinuclear platinum(ii) complexes with 1,2,4-triazole derivatives as bridging ligands

A series of new dinuclear platinum(ii) complexes with the general formula [Pt₂(μ-HL)₄] (1-4), where H₂L is 4-[(5-chloro-2-hydroxy-benzylidene)-amino]-3-R-1,2,4-triazole-5-thione: R = H (1), methyl (2), ethyl (3) and propyl (4), were synthesized and characterized. The X-ray crystal structures of 2, 3 and 4 reveal that the two platinum atoms form a paddlewheel core with four chelating triazole ligands as bridges, revealing a radically different structure than those of the traditional anticancer platinum(ii) complexes. These complexes show higher in vitro antiproliferative activity against human liver hepatocellular carcinoma (HepG2) and human breast adenocarcinoma (MCF7) than human lung cancer (A549) and human normal hepatocyte (HL-7702) cell lines. In particular, 3 exhibits antiproliferative activity (IC₅₀ = 5.5 μM) against HepG2 cells comparable to that of cisplatin. Different from the traditional anticancer platinum(ii) complexes with high DNA affinity, 3 binds very weakly to DNA. Upon comparison, it exhibits potent inhibiting activity against protein tyrosine phosphatases 1B (PTP1B, IC₅₀ = 16 μM) through possible binding to its active sites and its binding constant is 5.28 × 10⁴ M^-1. The results suggest that the antiproliferative mechanism of 3 against HepG2 cells may be different from that of cisplatin.

Palladium-modified functionalized cyclodextrin as an efficient and recyclable catalyst for reduction of nitroarenes

A kind of palladium-modified functionalized cyclodextrin catalytic system was synthesized and characterized. It showed high activity in the reduction of nitroarenes with the absence of sodium borohydride in water at room temperature.

Synthesis, cytotoxicity, induction of apoptosis, and interaction with DNA of dinuclear platinum(II) complexes

Six dicarboxylato-bridged dinuclear platinum(II) complexes S1-S6, with a newly designed chiral ligand, 2-{[(1R,2R)-2-aminocyclohexyl]amino}propanoic acid (HL), were prepared and spectrally characterized. The in vitro cytotoxicity of all resulting platinum(II) complexes was evaluated against human HCT-116, MCF-7, and HepG-2 tumor cell lines. The results show that all compounds exhibit positive biological activity toward HCT-116 and MCF-7 cell lines, of which complexes S3, S4, and S5, with succinate and its derivatives as bridges, showing better activity than the positive controls. Moreover, double-dyeing flow cytometric resection experiments indicate that the target compounds inhibit tumor cell growth by inducing apoptosis; gel electrophoresis experiments demonstrate the compounds' ability to prompt pET22b plasmid DNA degradation in almost the same way as oxaliplatin.